Regeneron Pharmaceuticals, Inc. earnings overview

REGN FY2026 Q1 · Calendar Q2 2026

Regeneron Pharmaceuticals, Inc.

Regeneron opened fiscal 2026 with a convincing top- and bottom-line beat: revenue up 19% year-over-year to $3.6 billion and non-GAAP EPS rising 15%, driven by accelerating DUPIXENT sales, EYLEA HD growing 52%, and steady Libtayo uptake. The pipeline delivered tangible milestones this quarter, including FDA approval of Otarmeni (a gene therapy for genetic hearing loss, offered free in the U.S.), positive Phase III data for cemdisiran in generalized myasthenia gravis, and advancement of the obesity candidate olatorepatide toward global Phase III. Management maintained the overall revenue and expense outlook while authorizing $3 billion in share repurchases and entering a Most-Favored-Nation pricing agreement with the U.S. government. Despite the operational strength, the stock fell roughly 6% on the report with continued downside drift, as investors appeared to focus on near-term…